Concepts (72)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 4 | 2016 | 154 | 0.850 |
Why?
|
| Bronchodilator Agents | 4 | 2014 | 49 | 0.850 |
Why?
|
| Fellowships and Scholarships | 3 | 2018 | 56 | 0.750 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 63 | 0.690 |
Why?
|
| Musa | 1 | 2020 | 1 | 0.650 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 23 | 0.640 |
Why?
|
| Colchicine | 1 | 2018 | 8 | 0.560 |
Why?
|
| Gout Suppressants | 1 | 2018 | 4 | 0.560 |
Why?
|
| Allopurinol | 1 | 2018 | 13 | 0.560 |
Why?
|
| Gout | 1 | 2018 | 14 | 0.550 |
Why?
|
| Spinal Diseases | 1 | 2018 | 24 | 0.550 |
Why?
|
| Steroids | 1 | 2018 | 39 | 0.550 |
Why?
|
| Ethanolamines | 2 | 2014 | 12 | 0.490 |
Why?
|
| Glucocorticoids | 1 | 2012 | 154 | 0.330 |
Why?
|
| Pulmonary Medicine | 2 | 2017 | 15 | 0.240 |
Why?
|
| Administration, Inhalation | 3 | 2014 | 56 | 0.210 |
Why?
|
| Treatment Outcome | 4 | 2018 | 3618 | 0.200 |
Why?
|
| Humans | 11 | 2021 | 34474 | 0.180 |
Why?
|
| Forced Expiratory Volume | 2 | 2012 | 92 | 0.180 |
Why?
|
| Internship and Residency | 2 | 2017 | 330 | 0.180 |
Why?
|
| Video Recording | 1 | 2021 | 64 | 0.170 |
Why?
|
| Teaching | 1 | 2021 | 65 | 0.170 |
Why?
|
| Education, Medical | 1 | 2021 | 73 | 0.170 |
Why?
|
| Learning | 1 | 2021 | 88 | 0.170 |
Why?
|
| Radiology, Interventional | 1 | 2018 | 5 | 0.140 |
Why?
|
| Physical Therapy Modalities | 1 | 2018 | 84 | 0.130 |
Why?
|
| Personnel Selection | 1 | 2017 | 16 | 0.130 |
Why?
|
| Muscarinic Antagonists | 1 | 2016 | 41 | 0.120 |
Why?
|
| Internal Medicine | 1 | 2015 | 57 | 0.110 |
Why?
|
| Critical Care | 1 | 2015 | 113 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 922 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 318 | 0.080 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2010 | 20 | 0.080 |
Why?
|
| Dinoprostone | 1 | 2010 | 37 | 0.080 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2010 | 95 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 565 | 0.080 |
Why?
|
| Cell Proliferation | 1 | 2010 | 628 | 0.070 |
Why?
|
| Adult | 2 | 2018 | 10015 | 0.070 |
Why?
|
| Job Application | 2 | 2017 | 6 | 0.060 |
Why?
|
| Delayed-Action Preparations | 2 | 2016 | 36 | 0.060 |
Why?
|
| Male | 2 | 2018 | 20697 | 0.050 |
Why?
|
| Time Factors | 2 | 2014 | 2352 | 0.030 |
Why?
|
| United States | 2 | 2017 | 4267 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2016 | 107 | 0.030 |
Why?
|
| Forecasting | 1 | 2016 | 153 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2014 | 105 | 0.030 |
Why?
|
| Reference Values | 1 | 2014 | 265 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 306 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 633 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2014 | 509 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2014 | 597 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 755 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 803 | 0.020 |
Why?
|
| Isoproterenol | 1 | 2010 | 19 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 57 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2010 | 41 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2010 | 46 | 0.020 |
Why?
|
| Albuterol | 1 | 2010 | 19 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2010 | 31 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2010 | 72 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 71 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2010 | 148 | 0.020 |
Why?
|
| Trachea | 1 | 2010 | 56 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 216 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 264 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2010 | 152 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2366 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 1506 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 887 | 0.020 |
Why?
|
| Aged | 1 | 2014 | 10998 | 0.010 |
Why?
|
| Middle Aged | 1 | 2014 | 12703 | 0.010 |
Why?
|
| Female | 1 | 2014 | 21490 | 0.010 |
Why?
|